Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
NCT03910543
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Sarcoidosis
Granuloma Annulare
Interventions
DRUG:
Tofacitinib 5 mg twice daily
Sponsor
Yale University
Collaborators
[object Object]